In a filing, MoonLake Immunotherapeutics revealed its Chief Financial Officer Bodenstedt Matthias acquired Company’s shares for reported $98808.0 on Oct 08 ’25. In the deal valued at $9.09 per share,10,870 shares were bought. As a result of this transaction, Bodenstedt Matthias now holds 627,536 shares worth roughly $6.32 million.
Then, Chen Bihua sold 6,494,151 shares, generating $46,827,628 in total proceeds. Upon selling the shares at $7.21, the Former 10% Owner now owns 2,000,000 shares.
Before that, Chen Bihua sold 5,827 shares. MoonLake Immunotherapeutics shares valued at $40,556 were divested by the Former 10% Owner at a price of $6.96 per share. As a result of the transaction, Chen Bihua now holds 1,994,173 shares, worth roughly $20.08 million.
H.C. Wainwright downgraded its MoonLake Immunotherapeutics [MLTX] rating to a Neutral from a a Buy in a research note published recently. A number of analysts have revised their coverage, including Goldman’s analysts, who decreased its forecast for the stock in early October from “a Buy” to “a Neutral”. Wolfe Research also remained covering MLTX and has decreased its forecast on September 30, 2025 with a “an Underperform” recommendation from previously “an Outperform” rating. Citigroup revised its rating on September 30, 2025. It rated MLTX as “a Neutral” which previously was an “a Buy”.
Price Performance Review of MLTX
On Monday, MoonLake Immunotherapeutics [NASDAQ:MLTX] saw its stock jump 5.78% to $10.07. Over the last five days, the stock has gained 7.64%. MoonLake Immunotherapeutics shares have fallen nearly -78.39% since the year began. Nevertheless, the stocks have fallen -81.40% over the past one year. While a 52-week high of $62.75 was reached on 09/26/25, a 52-week low of $5.95 was recorded on 09/29/25.
Levels Of Support And Resistance For MLTX Stock
The 24-hour chart illustrates a support level at 9.73, which if violated will result in even more drops to 9.38. On the upside, there is a resistance level at 10.25. A further resistance level may holdings at 10.42.
How much short interest is there in MoonLake Immunotherapeutics?
A steep rise in short interest was recorded in MoonLake Immunotherapeutics stocks on 2025-10-15, dropping by 58074.0 shares to a total of 4.89 million shares. Yahoo Finance data shows the prior-month short interest on 2025-09-15 was 4.95 million shares. There was a decline of -1.19%, which implies that there is a negative sentiment for the stock.
